We also assessed the association of race/ethnicity, gender, and socioeconomic status with SGLT2 inhibitor use among commercially insured patients with type 2 diabetes in the US, including those with heart failure with reduced ejection fraction (HFrEF), CKD, and atherosclerotic cardiovascular disease (ASCVD); individuals with these comorbidities were evaluated because of the demonstrated benefit of SGLT2 inhibitor use in these particular subgroups. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.